Pernix Therapeutics Holdings Stock Rating Lowered by Cantor Fitzgerald (PTX)
Pernix Therapeutics Holdings (NYSE:PTX) was downgraded by equities researchers at Cantor Fitzgerald from a “hold” rating to a “sell” rating in a research report issued on Monday, TheFlyOnTheWall.com reports.
Shares of Pernix Therapeutics Holdings (NYSE:PTX) traded down 7.88% during mid-day trading on Monday, hitting $2.22. 248,743 shares of the company’s stock traded hands. Pernix Therapeutics Holdings has a 52-week low of $1.68 and a 52-week high of $8.34. The stock has a 50-day moving average of $2.45 and a 200-day moving average of $2.85. The company’s market cap is $82.5 million.
Pernix Therapeutics Holdings (NYSE:PTX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.13) by $0.04. The company had revenue of $18.30 million for the quarter, compared to the consensus estimate of $23.06 million. During the same quarter last year, the company posted ($0.03) earnings per share. On average, analysts predict that Pernix Therapeutics Holdings will post $-0.61 earnings per share for the current fiscal year.
In other Pernix Therapeutics Holdings news, major shareholder Cooper C. Collins sold 62,038 shares of Pernix Therapeutics Holdings stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $2.35, for a total value of $145,789.30. The transaction was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Several other analysts have also recently commented on the stock. Analysts at Needham & Company reiterated a “buy” rating on shares of Pernix Therapeutics Holdings in a research note to investors on Wednesday, November 13th. They now have a $5.00 price target on the stock, down previously from $6.00. Separately, analysts at Guggenheim downgraded shares of Pernix Therapeutics Holdings from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, November 13th. They now have a $2.00 price target on the stock, down previously from $10.00. Finally, analysts at Stifel Nicolaus downgraded shares of Pernix Therapeutics Holdings from a “buy” rating to a “hold” rating in a research note to investors on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $3.60.
Pernix Therapeutics Holdings, Inc (NYSE:PTX) is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products for pediatric and adult indications in a range of therapeutic areas.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.